Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014 Volpara Solutions ... 1.2 at the 100th Annual Meeting of the ... 5, 2014 (RSNA Booth 1752 – South Hall). ... VolparaAnalytics and the rest of its innovative suite ... VolparaDoseRT, which enable personalized measurements of volumetric density, ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader ... 2014 Evening Dresses. All these fresh items are offered ... manager, the special offer is valid until Dec. 20, ... has been working well in the fashion industry for ... Their new dresses may be the best products for ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis Global ... the Aspergillosis clinical trial scenario. This report provides ... trials on Aspergillosis. It includes an overview of ... per the site of trial conduction across the ... disease clinical trials by their phase, trial status, ...
(Date:11/23/2014)... November 23, 2014 Pro Ace Care, a ... it will now be providing an 8 year warranty on ... water tank installations went up due to the impending winter ... its customers of the premium service that the company provides. ... year warranty on John Wood and Bradford hot water tanks. ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... popularity of weight training has grown over the past ... Injury Research and Policy of The Research Institute at ... injuries from weight training has increased as well. The ... were treated in U.S. hospital emergency departments between 1990 ...
... ... independent inspections and audits that enable AIB’s worldwide foodservice clients to lower business ... ... North America,s largest providers of third-party food safety audits , recently selected ...
... comment on risks from scans , TUESDAY, March 30 (HealthDay ... much radiation will get a public airing this week as ... meetings on what should be done to increase the safety ... seeking ideas to get manufacturers of the devices used for ...
... ... Can Benefit From A Posture Brace ( www.posturenow.com ) , ... (PRWEB) March 30, 2010 -- Within minutes ... the blogosphere was abuzz with comments about Chad Ochocinco’s poor posture. , , ,Chad’s ...
... ... Approach to Application Whitelisting by Verifying Insecure Software and Applications to Help Customers Improve ... ... Lumension , a global leader in endpoint management and security, today announced it has ...
... ... elder care law, released this statement concerning a March/April AARP article entitled "Love is (Not) ... for 44 years was forced to divorce in order to protect their remaining savings to ... off the mark , ...
Cached Medicine News:Health News:New national study examines weight training-related injuries 2Health News:New national study examines weight training-related injuries 3Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 2Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 3Health News:AIB International to Implement MetricStream for Compliance and Safety Audits 4Health News:Too Much Radiation? The FDA Wants to Know 2Health News:Too Much Radiation? The FDA Wants to Know 3Health News:Dancing With The Slouching Stars: Chad Ochocinco Fumbles When It Comes To Posture 2Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 2Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 3Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 4Health News:Lumension Partners With Citrix To Advance Desktop Virtualization Security 5Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 2Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 3
(Date:11/21/2014)... Calif. and VIENNA, Va. ... innovative in-home care provider that operates in ... a leading provider of remote caregiving technology. Alta will ... and existing client receiving homecare services. Logo ... this technology is the key to providing the kind ...
(Date:11/21/2014)... Fla. , Nov. 21, 2014   Rock ... announced that the Company is scheduled to present at ... San Francisco, CA on January 12-14, 2015. ... Chairman and CEO of Rock Creek Pharmaceuticals, will present ... molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... 16, 2007 - Amgen,(Nasdaq:AMGN) today presented the results ... the,efficacy and safety of Aranesp(R) (darbepoetin alfa) for ... not receiving,chemotherapy or radiotherapy ("the 103 study"). Aranesp ... EMEA in these patients. These,results were presented in ...
... WIRE)--Apr 16, 2007 - Arsenic, a naturally,occurring element, ... years, and even now remains a venerable constituent ... to the efforts of investigators supported,by grants from ... Walls," an arsenic derivative is being,utilized in therapy ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3
The electrically active helix of CapSureFix Novus lead is designed to extend easily for active fixation and retract for venous passage....
... presents the Streamline family of temporary sensing ... the gold standard in temporary pacing leads ... them easy to use and less traumatic ... Unipolar Pediatric Temporary Pacing Lead is designed ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: